CJC-1295 No DAC Better Than Mod GRF 1-29? — Real Peptides
CJC-1295 No DAC Better Than Mod GRF 1-29? — Real Peptides If you've spent time researching growth hormone-releasing peptides, you've likely encountered both 'CJC-1295 No DAC' and 'Mod GRF 1-29' offered by different suppliers. Sometimes at wildly different pric
CJC-1295 No DAC Better Than Mod GRF 1-29? — Real Peptides
If you've spent time researching growth hormone-releasing peptides, you've likely encountered both 'CJC-1295 No DAC' and 'Mod GRF 1-29' offered by different suppliers. Sometimes at wildly different price points. The truth? They're not two distinct compounds competing for your research budget. They're the same exact peptide with identical amino acid sequences, identical half-lives, and identical mechanisms of action. The only thing that differs is how suppliers choose to label them.
Our team has worked with both designations across hundreds of research protocols. The gap between understanding this correctly and wasting resources on perceived differences comes down to knowing what the original CJC-1295 molecule was, what happened when the DAC modification was removed, and why the research community settled on dual nomenclature for the same peptide.
Is CJC-1295 No DAC the same as Mod GRF 1-29?
Yes. CJC-1295 No DAC and Mod GRF 1-29 are identical peptides consisting of the same 29-amino-acid GHRH (growth hormone-releasing hormone) analog sequence. The 'No DAC' designation references the removal of Drug Affinity Complex technology from the original CJC-1295, leaving the base tetrasubstituted peptide that researchers now call either CJC-1295 No DAC or Modified GRF 1-29. Both names describe sermorelin's modified analog with four amino acid substitutions that extend plasma half-life to approximately 30 minutes.
The confusion stems from incomplete supplier labeling. When researchers see 'CJC-1295 No DAC' listed at one source and 'Mod GRF 1-29' at another, the assumption is that they're reviewing different compounds. They're not. The original CJC-1295 molecule developed by ConjuChem Biotechnologies included a Drug Affinity Complex modification that extended half-life to roughly 6–8 days by binding the peptide to serum albumin. When researchers wanted shorter-acting protocols without the DAC component, they referred to the base peptide either as 'CJC-1295 minus the DAC' or as 'Modified GRF 1-29' to distinguish it from native GRF 1-29 (sermorelin). Both terms reference the same tetrasubstituted analog. This article covers the chemical structure behind both names, why the dual labeling persists, and what that means for sourcing decisions in research settings.
The Chemical Reality Behind Both Names
Mod GRF 1-29 and CJC-1295 No DAC share an identical 29-amino-acid backbone derived from native GRF 1-29 (also called sermorelin). The modification involves four specific amino acid substitutions at positions 2, 8, 15, and 27 that increase resistance to enzymatic degradation by dipeptidyl peptidase-IV (DPP-IV) and prolong bioactivity. Without these substitutions, native GRF 1-29 has a plasma half-life of fewer than 7 minutes. Far too brief for most research applications requiring sustained receptor activation.
The tetrasubstituted version extends this to approximately 30 minutes, a window sufficient for pulsatile GH release studies without requiring the weeklong albumin-binding DAC modification. Structurally, position 2 substitutes D-Alanine for L-Alanine, position 8 replaces Alanine with Glutamine, position 15 swaps Alanine for Leucine, and position 27 substitutes Alanine for Leucine. These changes don't alter the peptide's binding affinity to GHRH receptors in the anterior pituitary. They solely extend its resistance to plasma peptidases that would otherwise cleave the molecule within minutes.
When you order from Real Peptides, both designations undergo identical synthesis protocols with exact amino-acid sequencing and batch-level purity verification. Because they're the same compound regardless of label.
Why Two Names for One Peptide Persist
The dual nomenclature exists because different research communities adopted different shorthand during early development. The term 'CJC-1295 No DAC' emerged after ConjuChem's original DAC-modified version entered clinical trials. Researchers needed language to specify the base peptide without the albumin-binding modification. 'Mod GRF 1-29' appeared in parallel as a descriptor distinguishing the tetrasubstituted analog from unmodified GRF 1-29 (sermorelin). Neither name was standardized by a regulatory body, so both stuck.
Suppliers compounded this by listing one name or the other based on market familiarity rather than chemical accuracy. Some peptide vendors use 'CJC-1295 No DAC' because customers recognize the CJC brand from early growth hormone studies. Others prefer 'Mod GRF 1-29' to avoid confusion with the discontinued DAC version, which is no longer commercially available. The result is identical peptides sold under different labels at price points that reflect branding rather than molecular difference.
Our experience shows this creates unnecessary procurement confusion. Research teams sometimes order both thinking they're acquiring distinct compounds for comparative studies. Only to discover through HPLC verification that the amino acid sequences match exactly. The variance isn't in the peptide; it's in supplier naming conventions that never converged on a single standard. Publications further muddy this by using both terms interchangeably without clarification, reinforcing the perception that they're separate entities.
CJC-1295 No DAC vs Mod GRF 1-29: Sourcing Comparison
Amino Acid Sequence
29-AA tetrasubstituted GHRH analog (D-Ala2, Gln8, Leu15, Leu27)
Identical sequence. No structural difference
Plasma Half-Life
~30 minutes post-injection
Same pharmacokinetic profile. Both resist DPP-IV degradation equally
Mechanism of Action
Binds GHRH receptors in anterior pituitary, stimulates pulsatile GH release
No mechanistic distinction. Receptor affinity and signaling pathways identical
Common Supplier Labeling
Marketed as 'CJC-1295 without DAC modification'
Marketed as 'Modified GRF 1-29' to distinguish from sermorelin
Naming reflects branding preference, not chemical difference
Typical Use in Research
Growth hormone secretion studies, body composition protocols
Interchangeable in all research applications
Professional Assessment
Both names describe the same peptide. Sourcing decisions should prioritize purity verification and synthesis quality, not label preference
Choose based on supplier reputation and batch testing, not nomenclature
Key Takeaways
CJC-1295 No DAC and Mod GRF 1-29 are identical peptides consisting of the same 29-amino-acid tetrasubstituted GHRH analog with four substitutions at positions 2, 8, 15, and 27.
Both share a ~30-minute plasma half-life due to DPP-IV resistance, contrasting with native GRF 1-29's sub-7-minute half-life and the discontinued DAC version's 6–8 day half-life.
The dual nomenclature persists because different research communities adopted different shorthand during development. 'No DAC' references removal of albumin-binding technology, while 'Mod GRF' distinguishes it from unmodified sermorelin.
Suppliers list one name or the other based on market familiarity rather than chemical accuracy, creating procurement confusion where researchers sometimes order both thinking they're distinct compounds.
Sourcing decisions should prioritize third-party purity verification and synthesis quality over label preference. At Real Peptides, both designations undergo identical batch-level HPLC testing because they're the same molecule.
Publications use both terms interchangeably without clarification, reinforcing the misperception that cjc-1295 no dac is better than mod grf 1-29 when no comparative advantage exists.
What If: CJC-1295 No DAC vs Mod GRF 1-29 Scenarios
What If a Supplier Lists Both at Different Prices?
Order the lower-priced option and request HPLC verification. If both peptides come from the same synthesis batch with identical amino acid sequences, the price difference reflects branding markup rather than quality variance. Suppliers sometimes charge more for 'CJC-1295 No DAC' because the CJC designation carries brand recognition from early growth hormone trials, while 'Mod GRF 1-29' is marketed as a specialty research analog. The peptides are chemically indistinguishable. Paying a premium for one label over the other delivers no added purity, potency, or research utility.
What If You've Already Purchased Both for Comparative Studies?
Run parallel HPLC and mass spectrometry analysis to confirm sequence identity. Most third-party testing labs will verify that both samples contain the same 29-amino-acid structure with identical tetrasubstitutions at positions 2, 8, 15, and 27. Once confirmed, consolidate protocols under a single designation to avoid redundant inventory. The confusion is nomenclature-based, not chemical. Treating them as separate compounds wastes research resources without yielding comparative data because there's nothing to compare.
What If a Publication References One but Your Supplier Stocks the Other?
Proceed with the available peptide. Research literature uses 'CJC-1295 No DAC' and 'Mod GRF 1-29' interchangeably depending on author preference and institutional familiarity. Replicating a protocol that specifies one name doesn't require sourcing that exact label if the amino acid sequence matches. Verify synthesis quality and request a certificate of analysis showing the four key substitutions, then cite both names in your methods section to clarify that you're using the same peptide referenced in the original study despite different supplier nomenclature.
The Blunt Truth About CJC-1295 No DAC vs Mod GRF 1-29
Here's the honest answer: asking whether cjc-1295 no dac is better than mod grf 1-29 is like asking whether H₂O is wetter than water. They're the same molecule with identical properties, and any supplier suggesting one outperforms the other is either misinformed or deliberately misleading. The only performance variable is synthesis quality. How precisely the four amino acid substitutions were sequenced, whether the lyophilization process preserved structural integrity, and whether third-party testing confirms >98% purity. Those factors matter. The label doesn't.
Our team works with research institutions that have wasted procurement budgets ordering both peptides under the assumption they'd yield different results. They don't. If a supplier lists both at different price points without disclosing they're identical, that's a sourcing red flag. It signals either a lack of peptide chemistry knowledge or intentional price arbitrage based on customer confusion. Real expertise means explaining the nomenclature history upfront and offering transparent batch verification regardless of which name you use to order.
Researchers face constant pressure to optimize protocols and justify compound selection. That pressure shouldn't translate into phantom decisions between peptides that don't differ. Focus resources on verifying purity, confirming proper reconstitution technique, and validating dosing schedules based on your model's receptor dynamics. Not on choosing between names that describe the same exact 29-amino-acid sequence.
The peptide synthesis process at Real Peptides follows identical protocols whether a researcher orders 'CJC-1295 No DAC' or 'Mod GRF 1-29'. Because functionally, operationally, and chemically, there is no distinction. We clarify this upfront because informed sourcing decisions drive better research outcomes. Vendor transparency matters more than brand recognition when molecular identity is at stake.
Frequently Asked Questions
Yes — CJC-1295 No DAC and Mod GRF 1-29 are identical peptides with the same 29-amino-acid sequence and four substitutions at positions 2, 8, 15, and 27. The dual naming convention arose because different research groups adopted different shorthand during development. ‘No DAC’ references the removal of Drug Affinity Complex technology from the original CJC-1295, while ‘Mod GRF’ distinguishes the tetrasubstituted version from native GRF 1-29 (sermorelin). Both terms describe the same molecule with a ~30-minute plasma half-life.
Suppliers use different names based on market familiarity and customer search behavior rather than chemical distinction. Some label it ‘CJC-1295 No DAC’ because the CJC brand carries recognition from early growth hormone studies, while others prefer ‘Mod GRF 1-29’ to avoid confusion with the discontinued DAC-modified version. The result is the same peptide sold under two labels, sometimes at different price points that reflect branding rather than molecular difference. Transparency in labeling separates informed suppliers from those exploiting nomenclature confusion.
There is no half-life difference — both peptides have a plasma half-life of approximately 30 minutes post-subcutaneous injection due to identical DPP-IV resistance from the four amino acid substitutions. This contrasts with native GRF 1-29 (sermorelin), which degrades in fewer than 7 minutes, and the original DAC-modified CJC-1295, which had a 6–8 day half-life from albumin binding. The tetrasubstituted version extends bioactivity enough for research protocols requiring pulsatile GH release without the weeklong pharmacokinetics of the DAC modification.
Yes — because they’re the same peptide, any protocol specifying one can be replicated with the other without adjusting dosing, timing, or reconstitution procedures. Research publications use both names interchangeably depending on author preference and institutional nomenclature standards. If you’re replicating a study that references ‘Mod GRF 1-29’ but your supplier stocks ‘CJC-1295 No DAC,’ verify the amino acid sequence matches (29-AA with D-Ala2, Gln8, Leu15, Leu27 substitutions) and proceed — the label variance won’t affect results.
Request third-party HPLC (high-performance liquid chromatography) analysis from your supplier showing >98% purity and confirming the presence of all four amino acid substitutions at positions 2, 8, 15, and 27. Mass spectrometry can further verify molecular weight matching the tetrasubstituted GHRH analog. Reputable suppliers provide batch-specific certificates of analysis without requiring separate requests — if a vendor lists both names but won’t disclose whether they’re sourced from the same synthesis batch, that’s a transparency red flag.
No — the question assumes a distinction that doesn’t exist. Both names describe the same peptide with identical receptor binding affinity, identical plasma half-life, and identical mechanisms of action at GHRH receptors in the anterior pituitary. Performance differences in research outcomes stem from synthesis quality (purity, proper lyophilization, accurate reconstitution) and protocol variables (dosing frequency, timing relative to GHRP co-administration, subject metabolic state) — not from choosing one label over the other.
The DAC (Drug Affinity Complex) modification extended CJC-1295’s half-life to 6–8 days by binding the peptide to serum albumin, but this created sustained GH elevation rather than pulsatile release — which doesn’t mimic natural physiology and raised concerns about receptor desensitization and feedback inhibition. Researchers needed shorter-acting protocols that preserved physiological GH pulsatility, leading to preference for the base tetrasubstituted peptide (CJC-1295 No DAC / Mod GRF 1-29) with its 30-minute half-life. The DAC version is no longer commercially available.
No — label preference is irrelevant if the underlying peptide is synthesized to the same purity and sequence standards. Prioritize suppliers who provide third-party batch testing, disclose synthesis methods, and clarify that both names describe the same molecule. A vendor charging different prices for ‘CJC-1295 No DAC’ versus ‘Mod GRF 1-29’ without explaining they’re identical signals either lack of peptide chemistry knowledge or intentional price arbitrage. Transparency and verifiable quality metrics matter far more than nomenclature.
Both peptides have a molecular weight of approximately 3367.97 g/mol because they consist of the same 29-amino-acid sequence with identical tetrasubstitutions. Mass spectrometry verification should confirm this molecular weight for any batch labeled either ‘CJC-1295 No DAC’ or ‘Mod GRF 1-29’ — significant variance suggests synthesis errors, incomplete substitution at the four key positions, or contamination. Molecular weight is one of several analytical markers suppliers should disclose in certificates of analysis alongside HPLC purity data.
Yes, but only because they’re the same peptide — you’d essentially be combining two aliquots of the same compound, which is procedurally redundant rather than contraindicated. There’s no research justification for mixing them unless you’re consolidating inventory from different suppliers that both stock the tetrasubstituted GHRH analog under different names. If you’re doing this, verify through HPLC that both sources synthesized the peptide to equivalent purity standards before combining batches — mixing high-purity and low-purity versions dilutes overall quality.